Regeneron Pharmaceuticals (REGN) Intangibles (2021 - 2026)

Regeneron Pharmaceuticals' Intangibles history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Intangibles rose 10.27% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 10.27% YoY), while the FY2025 annual figure was $1.3 billion, up 9.47% from the prior year.
• Intangibles was $1.3 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $1.3 billion in the prior quarter.
• In the past five years, Intangibles ranged from a high of $1.4 billion in Q3 2025 to a low of $155.0 million in Q2 2025.
• Historically, Intangibles has averaged $1.0 billion across 5 years, with a median of $1.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Intangibles jumped 13564.18% in 2022, then slumped 85.94% in 2025.
• A 5-year view of Intangibles shows it stood at $915.5 million in 2022, then rose by 13.45% to $1.0 billion in 2023, then increased by 10.59% to $1.1 billion in 2024, then climbed by 9.47% to $1.3 billion in 2025, then rose by 2.35% to $1.3 billion in 2026.
• The last three Intangibles figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.